A phase I trial of intravenous catumaxomab: A bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3

Cancer Chemotherapy and Pharmacology

Volumn 75, Issue 5, 2015, Pages 1065-1073

  Mau Sørensen, Morten ^a   Dittrich, Christian ^b   Dienstmann, Rodrigo ^c   Lassen, Ulrik ^a   Büchler, Wilfried ^b   Martinius, Holger ^d   Tabernero, Josep ^c  

^a FINSEN LABORATORY   (Denmark)

^b KAISER FRANZ JOSEF HOSPITAL   (Austria)

^c VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^d Neovii Biotech GmbH   (Germany)

Author keywords

Bispecific antibody; Catumaxomab; CD3; EpCAM; Phase I; Solid tumor

Indexed keywords

BISPECIFIC ANTIBODY; CATUMAXOMAB; CD3 ANTIGEN; CELL ADHESION MOLECULE; EPCAM PROTEIN, HUMAN; TUMOR ANTIGEN;

ADULT; AGED; BIOSYNTHESIS; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; HUMAN; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NEOPLASMS; PHASE 1 CLINICAL TRIAL; T LYMPHOCYTE;

ADULT; AGED; ANTIBODIES, BISPECIFIC; ANTIGENS, CD3; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; T-LYMPHOCYTES;

EID: 84938697464     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-015-2728-5     Document Type: Article

References (26)

1. Went P, Lugli A, Meier S et al (2004) Frequent EpCAM protein expression in human carcinomas. Hum Pathol 35:122-128
2. Went P, Vasei M, Bubendorf L et al (2006) Frequent high-level expression of the immunotherapeutic target EpCAM in colon, stomach, prostate and lung cancers. Br J Cancer 94:128-135
3. Spizzo G, Went P, Dirnhofer S et al (2004) High EpCAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat 86:207-213
4. Spizzo G, Went P, Dirnhofer S et al (2006) Overexpression of epithelial cell adhesion molecule (EpCAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol Oncol 103:483-488
5. Balzar M, Winter MJ, de Boer CJ et al (1999) The biology of the 17-1A antigen (EpCAM). J Mol Mod 77:699-712
6. Pauli C, Muenz M, Kieu C et al (2003) Tumor-specific glycosylation of the carcinoma-associated epithelial cell adhesion molecule EpCAM in head and neck carcinomas. Cancer Lett 193:25-32
7. Lindhofer H, Mocikat R, Steipe B et al (1995) Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J Immunol 155:219-225
8. Zeidler R, Reisbach G, Wollenberg B et al (1999) Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol 163:1246-1252
9. Zhang S, Zhang HS, Cordon-Cardo C et al (1998) Selection of tumor antigens as targets for immune attack using immunohistochemistry: protein antigens. Clin Cancer Res 4:2669-2676
10. Riesenberg R, Buchner A, Pohla H et al (2001) Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3). J Histochem Cytochem 49:911-917
11. Zeidler R, Mysliwietz J, Csanady M et al (2000) The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer 83:261-266
12. Schmitt M, Schmitt A, Reinhardt P et al (2004) Opsonization with a trifunctional bispecific (alphaCD3 x alphaEpCAM) antibody results in efficient lysis in vitro and in vivo of EpCAM positive tumor cells by cytotoxic T lymphocytes. Int J Oncol 25:841-848
13. Seimetz D, Lindhofer H, Bokemeyer C (2010) Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy. Cancer Treat Rev 36:458-467
14. Heiss MM, Murawa P, Koralewski P et al (2010) The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer 127:2209-2221
15. Petrelli F, Borgonovo K, Lonati V et al (2013) Regression of liver metastases after treatment with intraperitoneal catumaxomab for malignant ascites due to breast cancer. Target Oncol 8:291-294
16. Bezan A, Hohla F, Meissnitzer T et al (2013) Systemic effect of catumaxomab in a patient with metastasized colorectal cancer: a case report. BMC Cancer 13:618
17. Sebastian M, Passlick B, Friccius-Quecke H et al (2007) Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study. Cancer Immunol Immunother 56:1637-1644
18. Le Tourneau C, Lee JJ, Siu LL (2009) Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 101:708-720
19. Ruf P, Kluge M, Jäger M et al (2010) Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients. Br J Clin Pharmacol 69:617-625
20. Amacher DE (1998) Serum transaminase elevations as indicators of hepatic injury following the administration of drugs. Regul Toxicol Pharmacol 27:119-130
21. Suntharalingam G, Perry MR, Ward S et al (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355:1018-1028
22. Riechelmann H, Wiesneth M, Schauwecker P et al (2007) Adoptive therapy of head and neck squamous cell carcinoma with antibody coated immune cells: a pilot clinical trial. Cancer Immunol Immunother 56:1397-1406
23. Bugelski PJ, Achuthanandam R, Capocasale RJ et al (2009) Monoclonal antibody-induced cytokine-release syndrome. Expert Rev Clin Immunol 5:499-521
24. Burges A, Wimberger P, Kümper C et al (2007) Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study. Clin Cancer Res 13:3899-3905
25. Pietzner K, Vergote I, Santoro A et al (2014) Re-challenge with catumaxomab in patients with malignant ascites: results from the SECIMAS study. Med Oncol 31:308
26. Thomaidis T, Wörns MA, Galle PR et al (2014) Treatment of malignant ascites with a second cycle of catumaxomab in gastric signet cell carcinoma - a report of 2 cases. Oncol Res Treat 37:674-677